Avelox

ApprovedSmall molecule

Bayer

Avelox is one of 99 small molecule programs targeting Pelvic Inflammatory Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pelvic Inflammatory DiseaseActive, not recruiting

SinusitisActive, not recruiting

PneumoniaActive, not recruiting

Chronic BronchitisActive, not recruiting

Pelvic Inflammatory DiseasePhase 3

Active, not recruiting

SinusitisApproved

Active, not recruiting

PneumoniaPhase 3

Active, not recruiting

Chronic BronchitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

Avelox

Bayer

Approved

4 2

Primaxin

Pfizer

Preclinical

2 3

Prevacid

Takeda

Preclinical

1 4

Innohep

Alnylam Pharmaceuticals

Preclinical

1 5

Neutrexin

WWest Japan Thoracic Oncology Group

Preclinical

12 6

Primsol

CConrado Roberto Hoffmann Filho

Preclinical

2 7

Retrovir

BBp Consulting, Inc

Preclinical

2 8

Zantac 150

CChattem

Preclinical

2 9

Tagamet

DDT MedTech, LLC

Preclinical

1 10

Mucinex

AAultman Health Foundation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pneumonia4 trials

Efficacy and Safety of Sequential IV/PO Moxifloxacin in Comparison to IV Levofloxacin Plus IV Ceftriaxone Followed by PO Levofloxacin, in the Treatment of Patients With Community-acquired Pneumonia

Completed· Bayer logo

Bayer·Phase 3·NCT00431678·738 enrolled

A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia

Completed· Bayer logo

Bayer·Phase 3·NCT00717561·60 enrolled

BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia

Completed· Bayer logo

Bayer·Phase 3·NCT01045902·139 enrolled

Show 1 more trial

Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia

Completed· Bayer logo

Bayer·Phase 4·NCT00665327·401 enrolled

Chronic Bronchitis2 trials

Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic Bronchitis

Completed· Bayer logo

Bayer·Phase 4·NCT00656747·1,372 enrolled

Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis

Completed· Bayer logo

Bayer·Phase 3·NCT00473460·1,404 enrolled

Sinusitis2 trials

Treatment of Patients With Acute Sinusitis

Completed· Bayer logo

Bayer··NCT00930488·6,777 enrolled

Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox

Completed· Bayer logo

Bayer·Phase 4·NCT00668304·192 enrolled

Chronic Respiratory Disease1 trial

Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease

Completed· Bayer logo

Bayer··NCT01690533·497 enrolled

Safety and Efficacy1 trial

Dragon Study (the Safety and Efficacy for Treatment of Patients With Complicated Intra Abdominal Infections)

Completed· Bayer logo

Bayer·Phase 3·NCT00769171·364 enrolled

4 more indications

Buprenorphine1 trial

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers

Completed·PPurdue Pharma LP·Phase 1·NCT01148537·132 enrolled

Efficacy and Safety1 trial

A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs

Completed· Bayer logo

Bayer·Phase 3·NCT00828971·16 enrolled

Pelvic Inflammatory Disease1 trial

Uncomplicated Pelvic Inflammatory Disease. Treatment With Moxifloxacin.

Completed· Bayer logo

Bayer·Phase 3·NCT00683865·749 enrolled

Unspecified2 trials

Influence of Moxifloxacin on QTc Interval in Healthy Subjects for Positive Control Validation

Completed· Bayer logo

Bayer·Phase 1·NCT01014247·56 enrolled

CAEB071 Thorough QTc Study in Healthy Volunteers

Completed· Novartis logo

Novartis·Phase 1·NCT01594255·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Avelox. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Avelox compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Avelox. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Bayer

Avelox

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pneumonia4 trials

Chronic Bronchitis2 trials

Sinusitis2 trials

Chronic Respiratory Disease1 trial

Safety and Efficacy1 trial

Buprenorphine1 trial

Efficacy and Safety1 trial

Pelvic Inflammatory Disease1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News